Systematic Review on Randomized Controlled Trials for Treatment of Coronary Heart Disease by Tongxinluo Capsule

【Objective】 To evaluate the differences in curative effect on coronary heart disease between Tongxinluo capsule and western medicine like Isosorbide Dinitrate,and their safety.【Methods】 Two authors collected data and evaluated the quality of the included studies independently.The data were quantified by meta-analysis to review the adverse drug reactions.【Results】(1)Test of the combined curative effect of 17 studies showed an OR affiliate of 2.38,95%,and the confidence interval of OR was [1.83,3.09],P 0.01.The result of meta-analysis was statistically significant;(2)Test of the combined curative effect based on the cardiograms in 12 articles showed an OR affiliate of 2.08,95%,and the confidence interval of OR was [1.54,2.82],P0.01;(3)Four studies reported that obvious side effects were not detected in patients taking Tongxinluo capsule.Some patients were reported to have adverse reactions such as gastrointestinal tract disorder and headache in 11 articles,in which 17 patients were included in the Tongxinluo capsule group(2.64%),while 63 patients were included in the control group(10.92%);(4)By examining the results of blood,urine,and excrement tests,liver and renal functions,cardiac creatase,and electrolytes before and after the trial,we did not find any significant changes.【Conclusion】 Now we have evidence to indicate that the Tongxinluo capsule can improve curative effect better than Isosorbide Dinitrate.Due to the limited quality of the included studies,the curative effect will be evaluated by high quality RCT.